Clinical Results
Brella is proven to achieve key efficacy endpoints, including significant reductions in HDSS* and GSP,** with significant improvements in Quality of Life4
The majority of Brella-treated patients experienced
50%or greater reduction in sweat
production based on GSP4
HDSS* and GSP** Efficacy Endpoints
(at 4 weeks post-treatment)
Percent of Participants or
Gravimetric Sweat Production (GSP)
Primary Endpoint: Percent of participants achieving HDSS 1 or 2
Percent of participants achieving 2 points or greater improvement in HDSS
Percent of participants achieving 50% or greater reduction in gravimetric sweat production (GSP)
Mean reductions in GSP (mg produced in 5 min.)
Level of Bother and Impact of Sweat
(at 4 weeks post-treatment)
Reductions in level of Bother and
Impact on Daily Activities (5-point scale)
Reductions in sweat level of
Bother (5-point scale)
Reductions in sweat level of Impact on Daily Activities (5-point scale)
*HDSS- Hyperhidrosis Disease Severity Scale
**GSP- Gravimetrio Sweat Production
of patients, after one Brella treatment, indicated that sweat never or sometimes interfered with daily activities4
64%
of patients, after one Brella treatment, indicated that sweat never or sometimes interfered with daily activities4
LASTING
RESULTS
48% and 43% of Brella-treated patients maintained reduced underarm sweating at weeks 14 and 16, respectively4
QUALITY
OF LIFE
Brella is proven to significantly reduce excessive underarm sweat production and its negative impact on quality of life, including taking multiple showers per day, frequently changing shirts, and avoiding social situations. Brella also significantly reduces frustration and embarrassment and improves confidence.5
Brella is proven to significantly reduce excessive underarm sweat production and its negative impact on quality of life, including taking multiple showers per day, frequently changing shirts, and avoiding social situations. Brella also significantly reduces frustration and embarrassment and improves confidence.5
Brella was well tolerated. All adverse events were mild or moderate and transient. 78% of Brella-treated subjects reported no adverse events. 22% of Brella-treated subjects reported mild to moderate adverse events, such as mild irritation and redness, that mostly resolved within 2 weeks.4
Brella-treated patients experienced a significant physical and emotional improvement in quality of life5
SAHARA 7 Sweat Stressors: Negative Impact of Sweat on Daily Quality of Life (QoL) & Positive Impact of Brella™ at 4 and 12 Weeks
Before Brella Treatment
(Baseline)
4 weeks after Brella
(Brella patients improved)
12 weeks after Brella
(Brella patients improved)
Seven Questions from the SAHARA Clinical Study designed to assess the impact of sweating on both physical activities and psycho-social factors
